GlassScriptPhysician profile
Rodrigo B Mata
NPI 1033148176
$4,569.53
in general payments reported to CMS, 2019-2025
31 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $543 · 2021: $663 · 2022: $521 · 2023: $839 · 2024: $689 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $790.89 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $599.28 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $517.49 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $383.45 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.37 | 2019-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $227.53 | 2021-2023 | |
| Abbott Laboratories | $183.32 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Recor Medical INC | $181.33 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Abbvie INC. | $176.72 | 2021-2025 | |
| Pfizer INC. | $135.70 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $128.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $83.21 | 2019-2022 | |
| Exact Sciences Corporation | $80.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $73.43 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $72.17 | 2024-2025 | Zenpep |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $72.10 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.71 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $63.41 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $49.40 | 2021-2024 | Xarelto |
| Allergan, INC. | $46.07 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $42.43 | 2024-2025 | Rexulti |
| Eisai INC. | $40.15 | 2021 | |
| Sanofi-Aventis U.S. LLC | $36.86 | 2020-2021 | |
| Dexcom, INC. | $33.75 | 2024 | Dexcom G6 Transmitter |
| Nevro Corp. | $32.87 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.66 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.02 | 2023 | |
| Philips North America LLC | $18.54 | 2020 | |
| Sanofi Pasteur INC. | $16.17 | 2019 | |
| Lundbeck LLC | $15.68 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $15.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrigo Mata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.